High-Dose Wegovy Delivers 28% Weight Loss as Q1 Uptake Accelerates
Novo Nordisk's high-dose Wegovy achieved near 28% weight loss in early responders during clinical evaluations, underscoring the drug's potency. In Q1, the newly launched Wegovy pill saw rapid U.S. uptake while adjusted sales dipped due to lower realized prices despite obesity-franchise expansion and pipeline milestones.
1. High-Dose Wegovy Trial Results
Recent clinical evaluations of the high-dose Wegovy formulation demonstrated near 28% average weight loss among early responders, highlighting its enhanced efficacy over standard doses.
2. Rapid U.S. Uptake of Wegovy Pill
The first-quarter roll-out of the Wegovy oral pill in the United States saw rapid uptake, driven by physician demand and patient preference for non-injectable obesity treatments.
3. Sales Performance and Pricing Headwinds
Adjusted sales in Q1 declined as realized prices fell, offsetting volume gains from increased prescriptions and pressuring short-term revenue growth.
4. Pipeline and Regulatory Milestones
Novo Nordisk advanced multiple obesity and diabetes pipeline candidates and secured key regulatory milestones, reinforcing its long-term growth prospects beyond Wegovy.